Biogen (BIIB) Net Cash Flow (2009 - 2026)

Biogen (BIIB) has reported Net Cash Flow for 18 consecutive years, with $392.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 107.51% year-over-year to $392.2 million; the TTM figure through Mar 2026 stood at $734.8 million (down 52.11% YoY), while the FY2025 annual figure was $531.6 million, down 61.83% from the prior year.
• Net Cash Flow came in at $392.2 million for Q1 2026 at Biogen, up from -$856.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $1.1 billion in Q3 2025, with the low at -$1.3 billion in Q4 2023.
• Average Net Cash Flow over 5 years is $66.2 million, with a median of $47.6 million recorded in 2024.
• The largest YoY upside for Net Cash Flow was 718.59% in 2022 against a maximum downside of 522.92% in 2022.
• Year by year, Net Cash Flow stood at -$323.5 million in 2022, then tumbled by 297.5% to -$1.3 billion in 2023, then jumped by 158.34% to $750.2 million in 2024, then sank by 214.21% to -$856.8 million in 2025, then soared by 145.77% to $392.2 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $392.2 million, -$856.8 million, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.